| DESCRIPTION | - HELMUT STRASSER; CHRISTIAN WEBER, "On the asymptotic theory of permutation statistics", MATHEMATICAL METHODS OF STATISTICS, (1999), vol. 8, pages 220 - 250 | - |
| DESCRIPTION | - HOTHOM T ET AL., "Unbiased Recursive Partitioning: A Conditional Inference Framework", JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS, (2006), vol. 15, no. 3, pages 651 - 674 | - |
| DESCRIPTION | - EISENHAUER EA ET AL., "New response evaluation criteria in solid tumours: Revised RECIST guideline, version 1.1", EUR J CANCER, (2009), vol. 45, doi:doi:10.1016/j.ejca.2008.10.026, pages 228 - 247, XP025841550 | |
| INTERNATIONAL-SEARCH-REPORT | - Nasser H Hanna ET AL, "Lume-lung 2: A multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy.", J Clin Oncol 31, 2013 (suppl; abstr 8034), (20130530), URL: http://meetinglibrary.asco.org/print/1167801, (20140703), XP055126749 [XP] 1-8 * the whole document * | - |
| INTERNATIONAL-SEARCH-REPORT | - SEIJI NIHO ET AL, "Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial", CANCER CHEMOTHERAPY AND PHARMACOLOGY, (20030701), vol. 52, no. 1, doi:10.1007/s00280-003-0618-8, ISSN 0344-5704, pages 19 - 24, XP055126966 [Y] 4,8 * abstract * | |
| INTERNATIONAL-SEARCH-REPORT | - EDGARDO S SANTOS ET AL, "Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor", INVESTIGATIONAL NEW DRUGS ; THE JOURNAL OF NEW ANTICANCER AGENTS, KLUWER ACADEMIC PUBLISHERS, BO, (20110225), vol. 30, no. 3, doi:10.1007/S10637-011-9644-2, ISSN 1573-0646, pages 1261 - 1269, XP035052857 [X] 1-8 * abstract * * page 1264, column r, paragraph l - page 1266, column l, paragraph 2 * * table 1 * | |
| INTERNATIONAL-SEARCH-REPORT | - STOPFER P ET AL, "9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT, PERGAMON, OXFORD, GB, vol. 7, no. 2, doi:10.1016/S1359-6349(09)71865-8, ISSN 1359-6349, (20090901), page 551, (20090901), XP026690671 [X] 1-3,5-7 * the whole document * [Y] 4,8 | |
| INTERNATIONAL-SEARCH-REPORT | - MARTIN RECK ET AL, "Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial", THE LANCET ONCOLOGY, (20140201), vol. 15, no. 2, pages 143 - 145, XP055126729 [XP] 1-8 * the whole document * | |
| INTERNATIONAL-SEARCH-REPORT | - M. RECK ET AL, "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer", ANNALS OF ONCOLOGY, (20110106), vol. 22, no. 6, doi:10.1093/annonc/mdq618, ISSN 0923-7534, pages 1374 - 1381, XP055126764 [X] 1-3,5-7 * abstract * * page 1375, column l, paragraph 2 * * table 2 * [Y] 4,8 | |
| INTERNATIONAL-SEARCH-REPORT | - R. C. DOEBELE ET AL, "A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer", ANNALS OF ONCOLOGY, (20120216), vol. 23, no. 8, doi:10.1093/annonc/mdr596, ISSN 0923-7534, pages 2094 - 2102, XP055126867 [A] 1-8 * abstract * | |
| INTERNATIONAL-SEARCH-REPORT | - P. M. ELLIS ET AL, "Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients", CLINICAL CANCER RESEARCH, (20100511), vol. 16, no. 10, doi:10.1158/1078-0432.CCR-09-2944, ISSN 1078-0432, pages 2881 - 2889, XP055126754 [X] 1-8 * abstract * * page 2885, column r, paragraph l * | |
| INTERNATIONAL-SEARCH-REPORT | - KEUN-WOOK LEE ET AL, "Weekly Low-Dose Docetaxel for Salvage Chemotherapy in Pretreated Elderly or Poor Performance Status Patients with Non-small Cell Lung Cancer", JOURNAL OF KOREAN MEDICAL SCIENCE, (20080101), vol. 23, no. 6, doi:10.3346/jkms.2008.23.6.992, ISSN 1011-8934, page 992, XP055126959 [Y] 4,8 * abstract * | |
| OPPOSITION | - "LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer", ClinicalTrial.gov, (20091209), pages 1 - 11, URL: https://clinicaltrials.gov/ct2/show/study/NCT00805194?term=NCT00805194&rank=1, XP055588414 | - |
| OPPOSITION | - "Lume Lung 2: BIBF 1120 Plus Pemetrexed Compared to Placebo Plus Pemetrexed in 2nd Line Nonsquamous NSCLC", Clinical Trial NCT00806819, (20081211), pages 1 - 11, URL: https://clinicaltrials.gov/ct2/show/study/NCT00806819?term=NCT00806819&rank=1, XP055588423 | - |
| OPPOSITION | - TOROK, S. et al., "Nintedanib (BIBF1120) in the treatment of solid cancers: an overview of biological and clinical aspects", Magy Onkol., (20120000), vol. 56, no. 3, pages 199 - 208, XP055588210 | - |
| OPPOSITION | - SANTOS et al., "Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor", Invest New Drugs, (20120000), vol. 30, pages 1261 - 1269, XP035052857 | |
| OPPOSITION | - MAJEM et al., "An update on molecularly targeted therapies in second- and third-line treatment in non-small cancer: focus on EGFR inhibitors and anti- angiogenic agents", Clin. Transl. Oncol., (20130129), vol. 15, pages 343 - 357, XP035367295 | |
| OPPOSITION | - MAJEM et al., "An update on molecularly targeted therapies in second- and third-line treatment in non-small cancer: focus on EGFR inhibitors and anti-angiogenic agents", Clin. Transl. Oncol., (20130129), vol. 15, pages 343 - 357, XP035367295 | |
| OPPOSITION | - EISENHAUER et al., "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1", European Journal of Cancer, (20090000), vol. 45, pages 228 - 247, XP025841550 | |
| OPPOSITION | - EISENHAUER et al., "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)", European Journal of Cancer, (20090000), vol. 45, pages 228 - 247, XP025841550 | |
| OPPOSITION | - EISENHAUER et al., "New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);", European Journal of Cancer, (20090000), vol. 45, pages 228 - 247, XP025841550 | |
| OPPOSITION | - STOPFER et al., "9152 A population pharmacokinetic analysis for BIBF1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer", European Journal of Cancer; Supplement, Pergamon ; Oxford, GB, (20090000), vol. 7, no. 2, page 551, XP026690671 | |
| OPPOSITION | - RECK et al., "Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small- cell lung cancer (LUME-Lung 11): a phase 3, double- blind, randomized controlled trial", Lancet Oncol, (20140109), vol. 15, pages 143 - 155, XP055126729 | |
| OPPOSITION | - RECK et al., "Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small- cell lung cancer (LUME-LUNG 1): a phase 3, double blind, randomised controlled trial", Lancet Oncol, (20140000), vol. 15, pages 143 - 155, XP055126729 | |
| OPPOSITION | - RECK et al., "Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small- cell lung cancer (LUME-Lung 1): a phase 3, double blind, randomised control trial", Lancet Oncol, (20140109), URL: http://dx.doi.org/10.1016/S1470- 2045(13)70586-2, XP055126729 | |
| OPPOSITION | - RECK, M. et al., "Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small- cell lung cancer (LUME-Lung 1): a phase 3, double- blind, randomized controlled trial", Lancet Oncol., (20140000), vol. 15, pages 143 - 55, XP055126729 | |
| OPPOSITION | - ZHANG et al., "Activation of the AXL Kinase Causes Resistance to EGFR-Targeted Therapy in Lung Cancer", Nat Genet, (20130201), vol. 44, no. 8, pages 852 - 860, XP055337477 | |
| OPPOSITION | - RECK et al., "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small- cell lung cancer", Annals of Oncology, (20110000), vol. 22, pages 1374 - 1381, XP055126764 | |
| OPPOSITION | - RECK et al., "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small- cell lung cancer", Annals of Oncology, (20110106), pages 1374 - 1381, XP055126764 | |
| OPPOSITION | - RECK et al., "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small- cell lung cancer", Annals of Oncology, (20110106), vol. 22, no. 6, pages 1374 - 1381, XP055126764 | |
| OPPOSITION | - RECK, M. et al., "A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIB 1120 in patients with relapsed advanced non-small- cell lung cancer", Annals of Oncology, (20110000), vol. 22, pages 1374 - 1381, XP055126764 | |
| OPPOSITION | - DOEBELE et al., "A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small- cell lung cancer", Annals of Oncology, (20120216), vol. 23, pages 2094 - 2102, XP055126867 | |
| OPPOSITION | - DOEBELE, R.C. et al., "A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small- cell lung cancer", Annals of Oncology, (20120000), vol. 23, pages 2094 - 2102, XP055126867 | |
| OPPOSITION | - KELLY, K. et al., "Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small- cell lung cancer (NSCLC) after failure of prior platinum- based therapy", J. Thorac. Oncol., (20120000), vol. 7, no. 6, pages 1041 - 1048, XP055588212 | |
| OPPOSITION | - HILBERG et al., "BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumour Efficacy", Cancer Res., (20080615), vol. 68, no. 12, pages 4774 - 4782, XP008111436 | |
| OPPOSITION | - ELLIS et al., "Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients", Clin Cancer Res, (20100511), vol. 16, no. 10, pages 2881 - 2889, XP055126754 | |
| OPPOSITION | - ELLIS et al., "Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non- Small Cell Lung Cancer Patients", Clinical Cancer Res, (20100000), vol. 16, no. 10, pages 2881 - 2889, XP055126754 | |
| OPPOSITION | - ELLIS et al., "Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients", Clinical Cancer Research, (20100511), vol. 16, no. 10, pages 2881 - 2889, XP055126754 | |
| OPPOSITION | - ELLIS, P.M. et al., "Phase I Open-Label Study of Continous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non-Small Cell Lung Cancer Patients", Clin. Cancer Res., (20100000), vol. 16, no. 10, pages 2881 - 9, XP055126754 | |
| OPPOSITION | - SCULIER et al., "First- and second-line therapy for advanced nonsmall cell lung cancer", Eur. Respir. J., (20090000), vol. 33, pages 915 - 930, XP055588363 | |
| OPPOSITION | - SCULIER et al., "First-and second-line therapy for advanced nonsmall cell lung cancer", Eur. Respir. J., (20090000), vol. 33, pages 915 - 930, XP055588400 | |
| OPPOSITION | - MARTIN RECK, "BIBF 1120 for the treatment of non-small cell lung cancer", Expert Opin. Investig. Drugs, (20100513), vol. 19, no. 6, pages 789 - 794, XP008170340 | |
| OPPOSITION | - RECK, "BIBF 1120 for the treatment of non-small cell lung cancer", Expert Opin. Investig. Drugs, (20100000), vol. 19, no. 6, pages 789 - 794, XP008170340 | |
| OPPOSITION | - STINCHCOMBE et al., "Considerations for Second-line Therapy of Non-Small Cell Lung Cancer", The Oncologist, (20080000), pages 28 - 36, XP055588366 | |
| OPPOSITION | - STINCHCOMBE et al., "Considerations for Second-line Therapy of Non-Small Cell Lung Cancer", The Oncologist, (20080000), vol. 13, pages 28 - 36, XP055588366 | |
| OPPOSITION | - GORI et al., "New antiangiogenics in non-small cell lung cancer treatment: Vargatef? (BIBF 1120) and beyond", Therapeutics and Clinical Risk Management, (20110000), vol. 7, pages 429 - 440, XP055588352 | |
| OPPOSITION | - GORI et al., "New antiangiogenics in non-small cell lung cancer treatment: Vargatef'M (BIBF 1120) and beyond", Therapeutics and Clinical Risk Management, (20110000), vol. 7, pages 429 - 440, XP055588352 | |
